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Abstract  (250  words  max)  
  
The  development  of  biological  agents  with  specific  immunological  targets  has  
revolutionised   the   treatment   of   a   wide   variety   of   paediatric   diseases   where  
traditional   immunosuppressive   agents   have   been   partially   ineffective   or  
intolerable.   The   increasing   requirement   for   pharmaceutical   companies   to  
undertake  paediatric  studies  has  provided   impetus   for  studies  of  biologics   in  
children.   The   assessment   of   biologic   agents   in   children   to   date   has   largely  
relied  upon  randomised  control  trials  using  a  withdrawal  design,  rather  than  a  
parallel   study   design.   This   approach   has   been   largely   used   due   to   ethical  
concerns   including  use  of  placebo   treatments   in  children  with  active  chronic  
disease,   and   justified   on   the   basis   that   treatments   have   usually   already  
undergone  robust  assessment  in  related  adult  conditions.  However,  this  study  
design   limits   the   reliability   of   the   data   and   can   confuse   the   interpretation   of  
safety  results.  Careful  on-­going  monitoring  of  safety  and  efficacy  in  real-­world  
practice   through   national   and   international   biologics   registries   and   robust  
reporting   systems   is   crucial.   The   most   commonly   used   biologic   agents   in  
children  target  TNF-­α,  IL-­1,  IL-­6  and  CTLA-­4.  These  are  most  frequently  used  
in   paediatric   rheumatic   diseases.   This   review   will   discuss   the   development  
and  assessment  of  biologics  within  paediatric  rheumatology  with  reference  to  
the  lessons  learned  from  use  in  other  sub-­specialties.    
  
Introduction:  
Biological   treatments   are   defined   as   ‘a   pharmacological   group   of   specific  
proteins   with   high   molecular   weight,   specifically   targeting   pro-­inflammatory  
cytokines  or  cell  surface  antigens'  [1].  Their  mechanism  of  action  contrasts  to  
traditional   immunosuppressives   and   disease  modifying   anti-­rheumatic   drugs  
(DMARDs)   like  methotrexate,  which   inhibit   the  overall   inflammatory  process.  
The  identification  of  the  role  of  the  pro-­inflammatory  cytokines  tumor  necrosis  
factor   (TNF)   alpha,   interleukin-­1β   (IL-­1β)   and   interleukin-­6   (IL-­6)   in  
experimental  arthropathy  models  and  human  disease  has  been  critical  to  the  
development  of  specific  biological  treatments  [2,  3].  Evolving  knowledge  of  the  
nature  of  such  cytokines   through  preclinical  studies  of   the   immunobiology  of  
synovial   fluid   harvested   from   patients   with   active   disease   and   the  
development  of   recombinant  genetic   techniques  has   facilitated  production  of  
humanised  monoclonal  antibodies  and  soluble  cytokine  receptors.  These  are  
able   to   almost   completely   eliminate   or   block   target   pro-­inflammatory  
cytokines.   Biologics   may   also   block   particular   cell-­to-­cell   interactions   and  
consequently   inhibit  cellular  activation  or  deplete  specific  cell   types   from   the  
circulation  [4,  5].  
  
Important   changes   in   patients,   families   and   healthcare   professionals  
expectations  have  contributed  towards  a  significant  and  continued  motivation  
for   developing   and   improving   clinical   outcomes   using   biologics   in   children.  
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Key  drivers  for  biologic  development  include:  recognition  of  the  need  for  true  
disease  suppression  for  the  prevention  of  joint  damage  in  rheumatoid  arthritis  
(RA),  and   identification  of   the  critical   role  of  TNF-­alpha   in   juvenile   idiopathic  
arthritis   (JIA)   [6,   7];;   growing   expectations   of   higher   standards   of   sustained  
clinical  improvement;;  the  goal  of  striving  for  complete  disease  remission,  both  
on   medication   and   more   importantly,   after   cessation   of   treatment   with   an  
ultimate  goal  of  disease  cure.    
  
Assessment  tools  used  in  clinical  trials  in  JIA:  
Table   1   summarises   how   clinical   response   is   assessed   and   defined   in   JIA  
clinical   trials.   The   magnitude   of   treatment   response   is   generally   defined   in  
terms  of  attainment  of  the  American  College  of  Rheumatology  Paediatric  30,  
50,  70,  90    (PedACR30,  50,  70,  90)  response,  which  assesses  the  percentage  
improvement  in  3  of  the  6  JIA  core  set  measures.  ‘Flare’  is  defined  in  terms  of  
worsening   of   these   core   set   measures   [8].   The   proportion   of   patients  
achieving  ‘inactive  disease’  or  ‘clinical  remission’  is  also  reported  [8,  9].    
  
Design  of  clinical  trials  in  paediatric  rheumatology:    
To  date,  many  biologics   trials  within  paediatric   rheumatology  have  used   the  
‘withdrawal  design’  (see  Figure  1).  All  trial  participants  are  initially  exposed  to  
the   drug.   Those   who   reach   a   predefined   response   are   randomised   to  
treatment  with  active  drug  or  placebo,  with  the  trial  primary  outcome  being  a  
predefined   disease   flare   [10]   (see   Table   1).   Efficacy   is   defined   by   the  
difference   in   the  number  of  patients   flaring,  and   the   time   taken   to   flare.  The  
rationale  for  this  trial  design  is  that  all  patients  receive  the  active  drug,  that  a  
smaller  sample  size  can  be  used  and  that  the  time  on  placebo  is  minimised,  
making   it   more   acceptable   to   parents   and   many   clinicians.   Such   biologic  
treatments   have   generally   already   been   shown   to   be   efficacious   in   robust  
parallel   design   randomised   control   trials   (RCTs)   in   related   adult   conditions  
(e.g.   RA),   providing   a-­priori   proof   of   efficacy   in   children.   However   in   some  
diseases   there   is  arguably   inadequate  overlap  between   the  pathogenesis  of  
adult-­onset   diseases   for   these   data   to   be   extrapolated   directly   to   paediatric  
diseases.  
  
The   safety   profile   of   the   study   drug   can   be   difficult   to   assess   when   a  
withdrawal  study  design  is  used  due  to  potential  for  a  ‘carry  over’  effect  during  
the  placebo  phase.  The  relatively  short  time  on  placebo  treatment  also  limits  
the   power   to   compare   the   active   drugs   safety   profile   with   placebo   [11].  
Therefore  although  such  RCTs  have  shown  important  efficacy  of  biologics  in  
paediatric  disease,  there  is  critical  need  for  long-­term,  open  label  studies  and  
registries   to   determine   the   long-­term   safety   profile   and   efficacy   of   biologic  
drugs.  The  withdrawal  study  design  may  preselect   responders  who  continue  
to  retain  their  response  throughout  all  phases  of  the  study,  due  to  the  placebo  
effect   [11,   12].   Inclusion   of   physicians’   and   parents’   global   assessments   of  
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disease  activity  as  part  of   the  core  set  measures  detailed   in  Table  1,   is  also  
susceptible  to  the  inadvertent  placebo  response,  whereby  the  child  and  parent  
may   report   improvement   as   they   are   keen   to   believe   that   their   has   been   a  
positive  response  [13,  14].    
  






Identification  and  efficacy:  
Etanercept  is  a  fully  human,  soluble  fusion  protein  that  binds  to  TNF-­α  and  -­β  
with   high   affinity,   preventing   binding   to   cell   surface   TNF   receptors   [15].  
Etanercept  was  the  first  biologic  treatment  to  be  used  in  JIA  following  a  multi-­
centre,   randomised,   placebo-­controlled   trial   in   69  methotrexate-­resistant   JIA  
patients  with  a  polyarticular  disease  course  [16].  At  the  end  of  the  initial  open-­
label  study,  74%  responded  to  etanercept  treatment,  achieving  a  PedACR30  
response.   In   the   double-­blind   phase,   81%  of   patients   on   placebo   flared,   as  
compared   with   28%   of   etanercept   treated   patients   (p=0.003).   The   median  
time   to  disease   flare  was  28  days   compared  with  116  days  with  etanercept  
respectively   (p<0.001)   [16].      Those   flaring   on   placebo   were   re-­started   on  
etanercept.   The   response   to   etanercept   improved   over   2   years   during   the  
open-­label  extension  phase,  with  63%  of  patients  achieving  clinical  remission  
[17].    
  
Etanercept  efficacy  noticeably  varied  according  to  JIA  subtype.  Children  with  
systemic-­onset  JIA  (SoJIA)  generally  responded  less  favorably  than  other  JIA  
sub-­types   [17-­19].   The   on-­going   multicentre   ‘CLinical   Study   In   Paediatric  
Patients   of   Etanercept   for   Treatment   of   enthesitis   related   arthritis   (ERA),  
psoriatic   arthritis   (PsA),   and   extended   oligoarthritis’   study   (CLIPPER)  
demonstrated   etanercept   to   be   effective   and   well   tolerated   in   patients   with  
these  specific  subtypes  of  JIA,  with  an  overall  PedACR  50,  70,  90  response  
and  inactive  disease  being  achieved  in  81%,  62%,  30%  and  12%  respectively  
[20].    
  
Longer-­term   outcomes   on   etanercept   are   generally   favorable.   The   German  
biologics   registry   has   shown   that   males   with   a   shorter   disease   duration,   a  
lower   active   joint   count,   lower   childhood   health   assessment   questionnaire  
(CHAQ)   disability   score   at   baseline,   are   more   likely   to   achieve   inactive  
disease  and  remission  on  etanercept  over  a  mean  of  4.6  years  [21].  Similarly,  
the  Dutch  biologics  register  has  shown  a  lower  CHAQ  score  at  baseline,  less  
DMARD   failures   prior   to   starting   etanercept   and   a   younger   age   at   onset   to  
also   be   predictive   of   achieving   an   excellent   response   to   etanercept,   15  
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months   after   initiation   of   treatment   [22].   Co-­administration   of   methotrexate  
raises   the  chance  of   remission,  especially   in  patients  with   rheumatoid   factor  
negative  polyarthritis  (odds  ratio  2.0,  p  =  0.03)  [21].    
  
Etanercept  is  currently  licensed  by  the  European  Medicines  Agency  (EMA)  for  
the   treatment  of  polyarticular   JIA   in   children  >4  years  old  who  have  had  an  
inadequate  response  to  methotrexate  or  who  are  intolerant  [23].  In  the  UK,  the  
National   Institute   for   Clinical   Excellence   (NICE)   guidelines   from   2002  
recommend  use  of  etanercept  in  children  with  an  active  polyarticular-­course  of  
JIA,  widening  it’s  use  to  patients  with  extended  oligoarthritis,  psoriatic  arthritis,  
enthesitis   related  and   systemic   onset   arthritis.   These  guidelines  are  due   for  
review  in  2015  [24].  
  
Long-­term  efficacy  and  safety:  
Long-­term  open  labeled  follow  up  of  the  original  etanercept  trial  over  8  years,  
showed   a   good   safety   profile   and   a   durable   response   with   sustained  
reductions   in   disease   activity   [17,   25,   26].   To   date,   some   2896   cumulative  
patient   years   of   safety   data   have   been   published   from   1273   patients   who  
have   individually   received  a  maximum  of  6.8  years  of  etanercept   (see  Table  
2)   [18,   19,   26-­29].   Both   the  Dutch   and  German   national   biologics   registries  
have  reported  a  decrease  in  the  rate  of  adverse  events  (AEs)  over  time  [19,  
27],  from  0.20  AEs/patient  during  the  first  year  of  treatment,  reducing  to  0.12  
AEs/patient/year  thereafter  [27].  The  Italian  JIA  cohort  reported  a  higher  rate  
of  AEs  over  a  mean  of  24.1  months  of  follow-­up  (0.51  AEs/patient/year)  [29].  
The  main  AEs  associated  with  etanercept  use  are  shown  in  Table  3.    
  
Cases  of  new  onset  /  worsening  uveitis  (see  table  3)  [18,  28-­30]  have  led  to  
avoidance  of  etanercept  if  uveitis  is  present  (see  adalimumab  section  below).  
Notably,   no   significant   adverse  events   (SAEs)  were   reported   from  a  French  
cohort  where  etanercept  was  administered  weekly  (dose  0.8mg/kg/week)  [18],  
and  further  studies  have  demonstrated  comparable  safety  /  efficacy  of  weekly  
and  twice  weekly  etanercept  administration  [30-­32].  Cases  of  pulmonary  and  
extra-­pulmonary  mycobacterium  tuberculosis   infection  have  been  reported   in  
children  with  JIA  on  anti-­TNF  treatment,  and  vigilance  for  the  condition  must  
continue   to   be  maintained   during   treatment,   despite   negative   pre-­treatment  
screening  [33,  34].    
  
Conflicting  results  exist  regarding  the  relative  safety  of  treating  with  etanacept  
and  methotrexate   in   combination.  Data   from   the  US,  Canada  and  Germany  
have   mainly   reported   a   similar   rate   of   AEs   in   children   with   JIA   receiving  
etanercept   alone   or   in   combination   [27,   28],   although   a   trend   was   seen  
towards  a  higher  number  of  SAEs   in   those  on  combination   treatment   in   the  
German  registry  (p=0.06)  [27].  Preliminary  data  from  the  UK  biologics  registry  
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have  shown  nearly  twice  as  many  AEs  in  patients  on  combination  etanercept  /  
methotrexate  treatment  [35].    
  
Further  uses  of  Etanercept:  
Etanercept   use   has   been   reported   in   children   with:   Behcet’s   disease   [36],  
Familial   Mediterranean   fever   (FMF)   [37],   Tumour   necrosis   factor   receptor-­
associated   periodic   syndrome   (TRAPS)   [38],   Kawasaki   disease   [39],  
cutaneous   granulomas,   common   variable   immunodeficiency   and   idiopathic  
pneumonia   syndrome   following   allogeneic   hematopoietic   stem   cell  
transplantation   [40].   In  Crohn’s  disease   (CD),   it   is  avoided  due   to   reports  of  
triggering  of  inflammatory  bowel  disease  (IBD)  [41].  Clinical  trial  data  support  
its   use   in   severe   paediatric   plaque  psoriasis   [42];;   case   reports   indicate   that  




Identification  and  efficacy:  
Adalimumab   is  a  humanised  monoclonal  anti-­TNF  antibody,  administered   to  
JIA  patients  by  subcutaneous   injection  fortnightly.   In  RA,  concomitant  use  of  
methotrexate   prolongs   its   half-­life.   The   clinical   trial   of   adalimumab   in   JIA  
compared  efficacy  of  monotherapy  or  combination  therapy  using  a  withdrawal  
trial  design.  In  the  open  label  lead  in  phase  (first  16  weeks),  171  JIA  patients  
aged   between   4-­17   years   with   a   polyarticular   disease   course   were   treated  
with   24   mg/m2   of   adalimumab   on   alternate   weeks;;   84/171   continued   with  
previous  methotrexate  treatment.  PedACR  30,  50,  70  and  90%  response  was  
achieved   in   74%,   64%,   46%   and   26%   of   children   receiving   adalimumab  
monotherapy   compared   to   94%,   91%,   71%  and   28%   receiving   combination  
therapy  respectively.  During  the  double  blind  phase  of  the  study,  flares  were  
significantly   more   frequent   in   those   treated   with   methotrexate   /   placebo   or  
placebo  alone  [44].  A  preliminary  open  label  study  including  children  <4  years  
of  age  or  <15kg  has  shown  a  similar  improvement  in  PedACR  criteria,  and  a  
comparable   safety   profile   as   compared   to   older   children   [45].   In   Europe,  
adalimumab  is  licensed  for  use  in  active  polyarticular  JIA  (in  combination  with  
methotrexate   or   alone   if  methotrexate   is   inappropriate)   and   in   children  with  
enthesitis  related  arthritis  who  have  failed  to  respond  to  one  or  more  DMARD  
[23].   NICE   guidelines   relating   to   adalimumab   use   in   children   are   not   yet  
available  [24].  
  
Long-­term  efficacy  and  safety:  
Fewer   data   are   available   regarding   the   long-­term   safety   and   efficacy   of  
adalimumab   (see   Tables   2   and   3).   During   the   2-­year   RCT   open-­label  
extension   phase,   dosing   of   adalimumab   changed   with   patients   weighing  
<30kg   receiving   20mg   and   patients   weighing   ≥30kg   receiving   40mg.  
Adalimumab   showed   on-­going   efficacy   with   sustained   PedACR   responses  
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with  no  change  in  tolerability.  40%  of  patients  were  in  remission  by  the  end  of  
the  open  label  extension  [44].    
  
Cumulative   safety   data  on  398  patient   years   of   adalimumab  exposure  have  
been  published  from  171  patients  with  103  receiving  adalimumab  for  >3  years  
[44].  The  safety  profile  of  adalimumab  in  children  appears  similar  to  adults.  In  
2009,   the  Food  and  Drugs  Administration   (FDA)  collated  adalimumab  safety  
data   from   the   US   Healthcare   AE   Reporting   System,   including   108   SAEs  
occurring   following   in   utero   exposure   or   in   paediatric   patients  with   JIA,  CD,  
ulcerative   colitis   (UC),   uveitis,   psoriasis,   PsA   and   vasculitis.   Four   deaths  
occurred,  3   involving   in  utero  exposure;;   the  fourth  was  of  a  16  year  old  who  
developed   macrophage   activation   syndrome   (MAS),   pneumonia   and  
respiratory  failure.  There  were  24  reports  of  serious  infections  and  two  cases  
of  malignancy.   Both   patients   had   an   approximately   10-­year   history   of   using  
multiple   immunosuppressants,  making   it   difficult   to   establish   direct   causality  
[46].  
  
Further  uses  of  Adalimumab:  
A   recent   qualitative   study   indicated   uveitis   is   the   most   important   factor  
impacting   on   the   clinician’s   choice   between   adalimumab   and   etanercept,   in  
light   of   evidence   that   etanercept   can   contribute   to   worsening   or   new  
development   of   uveitis   (see   etanercept   section   above)   [19,   30,   47].   Two  
retrospective  observational  open  label  studies  have  explored  adalimumab  use  
in   JIA-­associated   uveitis.     One  demonstrated   adalimumab   to   be   effective   in  
16/18  patients  [48].  The  other  showed  7/20  (35%)  children  to  have  a  reduction  
in  uveitis  activity,  1/20  (5%)  had  worsening  activity,  and  12/20  (60%)  had  no  
change   [49].   Adalimumab   and   infliximab   have   been   compared   in   an   open  
label,  prospective,  multi-­centre  study  including  16  children  with  JIA-­associated  
uveitis,  3  with  idiopathic  uveitis  and  one  with  Behcet’s  disease.  No  significant  
difference  was  noted  between  the  treatments,  although  a  higher  probability  of  
uveitis   remission   was   seen   with   adalimumab   [50].   A   UK-­based   multicentre  
RCT  of  the  clinical  effectiveness,  safety  and  cost  effectiveness  of  adalimumab  
in  combination  with  methotrexate  versus  methotrexate  alone  for  the  treatment  
of  JIA  associated  uveitis  (SYCAMORE)  is  underway  [51].  
  
In   adult   CD,   adalimumab   is   effective   in   the   induction   and   maintenance   of  
remission,   reducing   hospital   admissions   and   related   surgery   [52-­55].  
Paediatric  studies  are  limited  to  open-­label  prospective  studies,  retrospective  
analyses  and  case  series  [56-­60].  The  IMAgINE  1  phase  III  RCT  investigated  
safety   and   dosing   of   adalimumab   treatment   in   191   children   with  moderate-­
severe   CD   [61].   Following   4   weeks   of   induction   treatment,   patients   were  
randomised  to  receive  low  or  high  dose  adalimumab.  36%  were  in  remission  
by   22   weeks,   with   no   difference   between   dosages   (p=0.075).   The   safety  
profile  was  comparable  to  adult  CD  studies  [61].    
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Adalimumab  is  also  used  in  paediatric  psoriasis  after  failure  of  other  systemic  
and  biologic  agents   [62-­64],  and  an  on-­going  RCT   is   testing   its  efficacy  and  
safety  paediatric  chronic  plaque  psoriasis   [65].  Adalimumab   is  both  effective  
and  well   tolerated   in   juvenile-­onset   AS   [66].   Patients   with   primary   systemic  




Identification  and  efficacy:  
Infliximab   is  a  chimeric  murine-­human  monoclonal  antibody  with  high  affinity  
for  TNF-­α,  administered  by  intravenous  (IV)  infusion  at  0,  2  and  4  weeks,  with  
subsequent   doses  being  administered  at   4-­8  week   intervals.  A  double  blind  
RCT   including   122   children   with   polyarticular   JIA   failed   to   demonstrate  
superiority   of   infliximab   over   placebo.   In   this   study   3mg/kg   of   infliximab   or  
placebo  was  given   for  14  weeks   in  combination  with  methotrexate.  A  higher  
proportion   of   patients   receiving   infliximab   reached   a   PedACR30   response,  
however   the   difference   between   the   treatment   groups   was   not   statistically  
significant   (p=0.12).  Patients   on  placebo   then  went   on   to   receive  high  dose  
infliximab  (6mg/kg).  By  week  52,  a  PedACR50  and  70  response  was  achieved  
in   70%   and   52%   of   patients   overall,   with   no   difference   depending   on   the  
infliximab  dosage   [70].  Despite   these   results,   infliximab   is   frequently  used   in  
refractory   polyarticular   JIA   (unlicensed   indication),   with   good   clinical   results  
reported.    
  
Long  term  efficacy  and  safety:  
In   the  RCT   discussed   above,   the   3mg/kg/dose   infliximab   group   had   double  
the   number   of   SAEs,   a   higher   rate   of   infusion   reactions   and   anaphylactic  
reactions  than  the  6mg/kg/dose  group,  correlating  with  an  increased  incidence  
of   anti-­infliximab   antibodies.   New   anti-­nuclear   (ANA)   and   double   stranded  
DNA   antibodies   (dsDNA)   were   also   seen   more   frequently   in   those   on   low  
dose   infliximab.  The  optimal  dosage  warrants   further   investigation,  as  some  
have   reported  doses  as  high  as  10-­20mg/kg/dose  as  being   rapidly  effective  
and  well  tolerated  [71].  
  
During  the  open  label  extension  phase  of  the  study  discussed  above  (weeks  
52-­204),   42/78   patients   discontinued   infliximab   due   to   consent   withdrawal,  
lack  of  efficacy  or  patient  /  physician  /  sponsor  requirements.  By  week  204  the  
proportion   of   patients   with   PedACR30,   50,   70,   90   responses   or   inactive  
disease  was  44%,  40%,  33%,  24%  and  13%  respectively.   Infusion  reactions  
occurred   in   32%   of   patients   with   a   higher   incidence   in   patients   positive   for  
infliximab   antibodies   [72].   Other   studies   have   also   looked   at   infliximab  
treatment  in  paediatric  rheumatology  practice  (see  Tables  2  and  3).    
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Further  uses  of  Infliximab:  
Infliximab   is   effective   as   induction   [73-­75]   and   maintenance   treatment   in  
children  with  CD  [61,  75,  76],  when  used  regularly  [77].  FDA  approval  for  use  
in   paediatric  CD  was   obtained   following   the   randomised,  multicentre,   open-­
label  REACH  study   in  children  with  moderate  –  severe  CD   [75].  58%  of   the  
112  patient   treated   achieved   clinical   remission   following  a   5mg/kg   induction  
dose.   Longitudinal   follow-­up   of   patients   on   maintenance   infliximab   showed  
56%  and  33%   to   still   be   in   remission  at  54  weeks  and  3  years   respectively  
[75,   76].   This   secondary   loss   of   response   associated   with   anti-­infliximab  
antibodies   may   be   reduced   by   giving   infliximab   regularly,   and   with   a  
concomitant   immunosuppressive   [78].   Infliximab   treatment   in   CD   is   also  
associated  with  reduced  rates  of  hospitalisation  and  surgery  for  complications  
of   active   disease   [79,   80]   and   improvements   in   growth   [81].   In   2010,  NICE  
recommended  that  infliximab  is  used  for  the  treatment  of  severe  active  CD  not  
responding  to  conventional  treatment,  or  where  conventional  treatment  cannot  
be  used  due  to  intolerance  or  contraindications  [24].  
  
Certolizumab  pegol  and  Golimumab  
  
Certolizumab   is   a   PEGylated   Fab   fragment   of   a   humanised   anti-­TNF-­   α  
antibody,  and  golimumab   is  a  humanised  monoclonal  anti   -­TNF-­  α  antibody.  
These   newer   TNF   antagonists   have   been   shown   to   be   effective   in   the  
treatment  of  RA,  PsA,  AS,  UC  and  CD   in  adults   [82-­87].  Certolizumab  does  
not   possess   an   Fc-­region   and   therefore   should   not   lead   to   cell   mediated  
cytotoxicity,   decreasing   the   infection   risk,   however,   this   does   not   seem   to  
have   translated   into   a   clear   reduction   in   infection   risk   in   clinical   practice.   It  
may   also   be   of   use   in   pregnancy,   as   the   lack   of   an   Fc-­region   will   prevent  
transplacental   transfer  [87].  Golimumab  is  similar  to  adalimumb  in  respect  to  
its   molecular   weight   and   it’s   affinity   for   soluble   and   transmembrane   TNF,  
however  golimumab  has  a   longer  half-­life  and  can  be  administered  monthly  
[4].  Currently   there  are  ongoing  multicentre   trials   looking  at   the  efficacy  and  
safety   on   golimumab   and   certolizumab   in   JIA   [88,   89].   Certolizumab   pegol  
and  golimumab  are  not  currently  licensed  for  use  in  children  [23].  
  




Identification  and  efficacy:  
Anakinra   is   an   interleukin-­1   (IL-­1)   receptor   antagonist   administered   by   daily  
subcutaneous  injection  at  a  dose  of  1-­2mg/kg/day.  It  has  not  demonstrated  a  
significant  benefit  over  placebo   in  polyarticular  JIA   [90],  but   in  a  multicentre,  
RCT   of   anakinra   in   SoJIA,   8/12   patients   on   anakinra   and   1/12   on   placebo  
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achieved   a   PedACR30   response.   9/10   of   the   placebo   treated   patients   who  
were   switched   to   anakinra,   subsequently   responded.   The   tolerability   of  
anakinra  was  comparable  to  placebo  [91].  
  
Use  of  anakinra  as  part  of   the   initial   therapeutic  strategy   in  SoJIA  has  been  
assessed   in   a   multicentre   case   series   including   46   patients.   Anakinra   was  
used   as   monotherapy   in   28%,   with   67%   and   33%   also   receiving  
corticosteroids  and  additional  DMARDs  respectively.  Fever  and  rash  resolved  
within  1  month  in  >95%,  and  CRP  /  ferritin  also  normalised  in  >80%  over  this  
time  period.  Persistence  of  arthritis  was  seen  in  39%,  27%  and  11%  after  1,  3  
and  >6  months  of   treatment,   respectively.   Inactive  disease  was  achieved   in  
8/10  patients  receiving  anakinra  monotherapy  [92].  In  another  study  including  
patients   who   had   previously   received   long-­term   corticosteroids   ±   DMARDs,  
the   clinical   response   to   anakinra   was   more   heterogeneous.   The   majority  
experienced   an   initial   amelioration   of   systemic   features   and   acute   phase  
reactants,   however,   subsequently   one   group   displayed   on-­going   disease  
remission  and  the  other  showed  a  tendency  towards  recurrence  [93].    
  
Long  term  efficacy  and  safety:  
Studies   looking   at   the   efficacy   and   safety   of   anakinra   beyond   1   year   are  
warranted.   The  main   AEs   reported   in   associated   with   IL-­1   blocker   use   are  
shown   in   Table   4.   Injection   site   reactions   were   the   most   common   AE,  
decreasing  over  time  [90,  94,  95].    
  
Further  uses  of  Anakinra:  
Anakinra   is   licensed   for   use   in   cryopyrin-­associated   periodic   syndrome  
(CAPS)  with  dramatic  amelioration  of  clinical  characteristics.  It  has  also  been  
shown   to   be   of   benefit   in   deficiency   of   the   interleukin-­1-­receptor   antagonist  
(DIRA),   nod-­like   receptor   protein-­12   (NLRP-­12)   associated   periodic   fever  
syndrome,  FMF  and  TRAPS.  A  variable  treatment  response  has  been  found  
in   Blau’s   syndrome,   pyogenic   sterile   arthritis,   pyoderma   gangrenosum   and  




Rilonacept   is   a   fusion   protein,   which   acts   as   a   long   acting   soluble   IL-­1  
receptor  with  a   longer  half-­life   than  anakinra.   In  an  RCT,  24  SoJIA  patients  
were  treated  with  weekly  rilonacept  (2.2-­4.4mg/kg,  maximum  dose  360mg)  or  
placebo  for  4  weeks.  23/24  patients  subsequently  entered  an  open-­label  trial  
lasting   up   to   24   months.   There   was   no   significant   difference   in   efficacy  
between  rilonacept  and  placebo  during  the  initial  double  blind  phase.  Within  3  
months,   fever   and   rash   resolved   in   all   patients   and   a   PedACR30,   50,   70  
response   of   78.3%,   60.9%   and   34.8%   respectively   was   seen   and  
subsequently  maintained.   All   patients   developed   an   AE   (see   Table   4),   with  
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13%  developing  an  SAE  and  discontinuing  treatment  [97].  Rilonacept  has  also  
been  used  in  CAPS  and  FMF  [96].  Rilonacept  is  not  currently  licensed  for  use  




Canakinumab   is   a   fully   human   monoclonal   anti-­IL-­1β   antibody   with   a   long  
half-­life,  given  monthly  by  subcutaneous   injection.   In  a  double  blind  study,  a  
PedACR30   response  of   84%  was   seen  at   15   days   post   treatment   in  SoJIA  
patients  who  received  a  single  dose  of  canakinumab  and  10%  who  received  
placebo   (p<0.001)   [98].   Patients   who   achieved   greater   than   a   PedACR30  
response  were  enrolled  into  a  phase  III  trial  with  a  two-­part  withdrawal  design.  
All   patients   initially   received   canakinumab   and   corticosteroid   tapering   was  
attempted   on   open   label   treatment.   45%   were   able   to   reduce   their  
corticosteroid   dosage   by   at   least   50%,   and   33%   discontinued   steroids   all  
together.   In   the   placebo   controlled   phase,   75%   on   placebo   flared,   as  
compared   to  26%   in   the  canakinumab  group   (relative   risk   reduction  of  64%,  
hazard   ratio   0.36;;   95%   CI:   0.17   to   0.75)   [99].   Canakinumab   was   initially  
licensed   for   treatment   of   CAPS,   but   it’s   license   has   been   extended   by   the  
FDA  and  EMA  to  include  the  treatment  of  SoJIA  patients  >  ≥2  years  old  [23,  
100].  NICE  guidance  is  not  yet  available.    
  
Safety:  
In   the   placebo-­controlled   phase   of   the   study   detailed   above,   one   patient  
developed   MAS   and   a   serious   infection   in   each   treatment   group.   Seven  
patients  developed  serious   infections  during   the  open   label   treatment  phase  
(two   associated   with   MAS).   There   were   two   deaths   associated   with  
cannakinumab   treatment   but   no   reports   of   cancer,   tuberculosis   or  
opportunistic  infection  (see  Table  4)  [99,  101].    
  
Further  uses  of  Canakinumab:  
Canakinumab  has  been  shown  to  be  effective  in  CAPS.  There  is  an  on-­going  





Identification  and  efficacy:  
Tocilizumab   is   a   humanised   monoclonal   antibody   that   targets   the   IL-­6  
receptor,   preventing   IL-­6   from  exerting  pro-­inflammatory   effects.  Serum  and  
synovial  IL-­6  levels  are  elevated  in  SoJIA  and  correlate  with  disease  activity,  
decreasing   with   effective   treatment   [102,   103].   The   first   phase   III   RCT   of  
tocilizumab   in   SoJIA   used   a   withdrawal   study   design.   56   Japanese   SoJIA  
patients   were   initially   treated   with   8mg/kg   of   tocilizumab,   2   weekly   over   6  
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weeks,   with   responders   subsequently   being   randomised   to   tocilizumab   or  
placebo  for  12  weeks.  A  PedACR30,  50,  70  response  was  achieved  in  91%,  
86%,  68%  respectively.  Flares  were  more  common  in  the  placebo  group  (83%  
vs.   20%,  p<0.0001).  By  48  weeks,   in   the  open-­label   extension,  PedACR30,  
50,  70  responses  were  achieved  in  98%,  94%,  90%  respectively  [104].    
  
In   a   multinational,   phase   III,   5-­year,   double   blind   RCT   (TENDER   trial),  
significantly   more   patients   on   tocilizumab   than   controls   achieved   a  
PedACR30,   50,   70   by  week   12   of   treatment   (85%,   71%,   37%   versus   24%,  
8%,   5%   respectively;;   p<0.0001).   A   progressive   improvement   in   treatment  
response  was  observed  during   the  52  week  open   label  extension,  with  59%  
reaching   an   ACR90   response   and   28%   attaining   clinically   inactive   disease  
[105].   Tocilizumabs   was   approved   by   the   FDA   and   NICE   in   2011,   for   the  
treatment   of   children   >2   years   old   with   SoJIA   who   have   not   responded  
adequately   to   non-­steroidal   anti-­inflammatory   drugs,   corticosteroids   and  




The  range  of  AEs  associated  with  tocilizumab  are  summarized  in  Table  5.  In  
the   Japanese   tocilizumab   phase   III   trial   mentioned   above   8.9%   developed  
anti-­tocilizumab   antibodies   and  mild-­moderate   infusion   reactions,   leading   to  
discontinuation  of  tocilizumab  in  most  patients  [106].  Within  the  TENDER  trial,  
infusion  reactions  occurred  in  16%  on  tocilizumab  and  5%  on  placebo  [105].  
  
Further  uses  of  Tocilizumab:  
Preliminary   results   from   the   global,   phase   III,   placebo-­controlled   CHERISH  
trial   of   tocilizumab   in   polyarticular   JIA   (American   College   of   Rheumatology  
conference,  2012,  abstract  number  1957)  have  revealed  a  significantly  higher  
PedACR30,   50,   70   response   with   tocilizumab   than   placebo,   with   65%  
attaining   an   ACR70   response   by   week   40.   48%   on   placebo   and   26%   on  
tocilizumab   flared   within   this   time   period   (p=0.0024)   [107].   An   open   label  




Identification  and  efficacy:  
Cytotoxic   lymphocyte-­associated   antigen-­4   (CTLA-­4)   is   a   potent   inhibitor   of  
the  co-­stimulatory  pathway  that  is  necessary  to  activate  T  cells.  Abatacept  is  a  
fully  human  soluble  fusion  protein  that  is  composed  of  a  modified  Fc  portion  of  
IgG1,   linked   to  CTLA-­4.   It   binds   to  CD80/CD86  on  antigen  presenting  cells,  
inhibiting   it’s   interaction   with   CD28   on   T-­cells,   thereby   inhibiting   T-­cell   co-­
stimulation  and  activation.   In  a  phase   III,  multinational,  double  blind,  RCT   in  
polyarticular   JIA   patients   using   a   withdrawal   design,   70%   of   patients  
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responded   to  abatacept  during   the  open   label   lead   in  phase.  Subsequently,  
flares  occurred   in  53%  of  patients   receiving  placebo,  and  20%  of  abatacept  
patients   (p=0.0003),  with   the  median   time   to   flare  being  shorter   in   those  on  
placebo.  PedACR30,  50,  70  and  90  responses  in  the  abatacept  and  placebo  
group  were  82%,  77%,  53%,  40%  and  69%,  52%,  39%  and  16%,  respectively  
[108].    
  
The   majority   (153/190)   of   patients   subsequently   entered   an   open   label  
extension  study,   for  a  median  of  35  months  (range  5.5-­47.8).  By  day  589,  a  
PedACR30,  50,  70,  90  and  100%  response  was  achieved  in  90%,  88%,  75%  
57%  and  39%  of  patients  who  had  been   treated  with  abatacept  during  both  
the   double   blind   and   extension   phases   of   the   study.   The   response   to  
abatacept   was   maintained   or   progressively   improved   over   the   studies  
duration,  with  73%  of  children  who  had  not  reached  a  PedACR30  response  at  
the  end  of  the  lead-­in  phase  subsequently  achieving  this  during  the  open  label  
extension  [109].  The  FDA  approved  abatacept  for  use  in  children  >6  years  old  
with  moderate   to  severe  JIA  of  a  polyarticular  course   in  2009,  with   the  EMA  
also  approving  it  in  2010.    
  
Safety:  
In   the   RCT   discussed   above,   the   number   of   AEs   was   similar   across   all  
treatment  groups.  The  AEs  reported  in  association  with  abatacept  are  shown  
in  Table  5.  No  patients  randomised  to  receive  abatacept  experienced  an  SAE,  
whereas  two  of  the  patients  receiving  the  placebo  developed  SAEs  (although  
placebo  patient’s   received   four  months  of  abatacept  prior   to   randomisation).  
Five  patients  experienced  infusion  reactions.  Anti-­abatacept  and  anti-­CTLA-­4  
antibodies  were   present   in   11%  of   the   149  patients  with   samples   available,  
but  did  not  correlate  with  occurrence  of  infusion  reactions  or  loss  of  treatment  
efficacy  [109].  
  
Further  uses  of  Abatacept:  
Abatacept  has  been  assessed  in  a  small  retrospective  case  series  of  patients  
with   severe   anti-­TNF-­   α   refractory   JIA   associated   uveitis.   All   patients  
responded  within   6  months   of   treatment  with   the   frequency   of   uveitis   flares  
decreasing   from   a  mean   of   3.7   episodes   to   0.7   episodes   /   6  month   period  
[110].  Clinical  studies  in  adults  are  investigating  use  of  abatacept  in  RA,  UC,  
CD,   diabetes   mellitus,   SLE,   graft   versus   host   disease,   uveitis,   Takayasu’s  





Rituximab  is  a  chimeric  anti-­CD20  monoclonal  antibody  that  binds  and  causes  
apoptosis  of  CD20  positive  B  cells,   leading  to   their  prolonged  depletion.   It   is  
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licensed   for   use   in   RA   and   has   shown   promising   results   in   children   for   a  
variety  of  off  label  indications  including  JSLE,  JIA,  primary  systemic  vasculitis,  
relapsed   non-­Hodgkins   lymphoma   and   leukemia,   chronic   immune  
thrombocytopenic   purpura,   autoimmune   hemolytic   anemia,   nephrotic  
syndrome,   acute   and   chronic   solid   organ   transplant   rejection   and   post  
transplantation   lymphoproliferative   disease   [111].   There   are   however   no  
RCTs  of  rituximab  use  in  children.  
  
In  paediatric  rheumatology  practice,  rituximab  is  most  frequently  used  in  JSLE  
despite   robust   evidence   for   its   efficacy   being   limited.   A   retrospective   case  
series   of   rituximab   treatment   in   19   JSLE   patients   with   severe   general  
symptoms  or   acute   life   /   organ   threatening  manifestations,   un-­responsive   to  
standard   treatment,   demonstrated   a   rapid   reduction   in   disease   activity   after  
two   infusions   in   the   majority   of   patients,   with   improvements   in   renal,  
immunological   and   haematological   parameters   and   no   serious   side   effects  
[112].   In   a   French   cohort,   11   children   with   severe   JSLE   received   2-­12  
infusions   of   rituximab   in   addition   to   standard   immunosuppressive   agents   in  
6/11  patients.  Remission  was  achieved  in  8/11  patients  and  maintained  over  a  
mean  of  13.2  months,  but  SAEs  occurred  in  45%  [113].  
  
The  largest  rituximab  study  in  JIA  included  55  children  with  refractory  disease  
(polyarticular   and   SoJIA   patients)   who   received   4   weekly   infusions   as  
necessary.  Within  6-­8  weeks  there  was  a  decrease  in  systemic,  articular  and  
laboratory   disease   manifestations,   and   by   24   weeks,   98%,   50%   and   40%  
achieved  an  ACR  30,  50,  70  response  [114].  Due  to  the  uncontrolled  nature  of  
the   study   and   the   range   of   concomitant  medications,   the   results   should   be  
interpreted  with  caution.   In  contrast   to  adults   treated  with   rituximab,  children  
may  develop   long   standing  B   cell   depletion  and  hypogammaglobuminaemia  




Belimumab  is  a  fully  human  monoclonal  antibody  which  blocks  soluable  BLyS,  
a  B-­cell   survival   factor  and  prevents   it   from  binding   to  B-­cell   receptors.  The  
FDA  and  EMA  approved  belimumab  use   in  adults  with  serologically  positive  
SLE   in   2011   following   the   outcome   of   the   BLISS   trials,   which   showed   that  
belimumab   was   associated   with   a   reduction   in   disease   activity,   prevented  
worsening  of  internal  organ  involvement  and  reduced  the  rate  of  severe  flares  
over   52   weeks   in   1684   patients   [116,   117].   Belimumab   is   currently   being  




Biologics  and  risk  of  malignancy:  
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In  2009,  the  FDA  reported  an  increased  risk  of  lymphoma  and  other  cancers  
associated   with   anti-­TNF   treatment   in   children   and   adolescents   in   light   of  
post-­marketing  surveillance  data.  Interpretation  of  these  data  is  complex  due  
to   the   potential   confounding   effects   of   concomitant   immunosuppressives  
(used   in   88%   reported   upon),   and   uncertainty   regarding   the   incidence   of  
malignancy   in   uncontrolled   inflammatory   diseases   [118].   A   Swedish   study  
looking   at   cancer   risk   in   biologic   naïve   JIA   patients   using   linkage   through  
national   databases   and   matched   general   population   comparators   found   an  
elevated   risk   of   malignancy   in   biologic   naïve   JIA   patients   in   whom   the  
diagnosis  was  made  during   the  past   20   years   [119].   In   the  FDA   report,   ten  
cases   of   hepatosplenic   T   cell   lymphoma   (HSTCL)   were   reported   in   IBD  
patients,  however,   the  concomitant  medications  used  (6-­mercaptopurine  and  
azathioprine)  are  also  independently  associated  with  HSTCL  [120].  Similarly,  
there  are  case  reports  of  non-­Hodgkin’s  lymphoma  in  JIA  patients  treated  with  
methotrexate  [121].    
  
Biologics  registries:  
In  order  to  understand  the  long-­term  safety  profile  of  biological  therapies  it  is  
important   to   collect   data   through   Registries   and   to   continue   data   collection  
into  adult  years.  Clearly  there  are  significant  challenges  involved  especially  as  
some   SAEs   (such   as   malignancy   are   likely   to   be   rare.   A   summary   of   the  
current  biologics  Registries  for  children  is  given  in  Table  6  and  it  is  hoped  that  
pooling   of   data   will   help   address   long-­term   safety   issues.   There   are  
challenges  with  the  governance  and  structure  of  data  pooling,  but  to  this  end,  
the   international   pharmacovigilance   databank   (Pharmachild)   has   recently  
started   [122].   Whilst   uncertainties   exist,   it   is   important   that   experienced  
specialist  teams  use  biological  agents,  that  patients  and  parents  are  aware  of  
the  rationale,  and  that  discussions  regarding  risk  versus  benefit  are  carefully  




The  development  of  biologics  for  use  in  children  has  significantly  changed  the  
treatment   pathways   of   a   wide   range   of   autoimmune   diseases,   enabling  
clinicians   to   aim   for   complete   disease   remission   in   complex   conditions   that  
were   previously   associated   with   long-­term   damage   and   disability.   Reliance  
upon   the   withdrawal   study   design   during   the   assessment   of   biologics   in  
children  has  complicated  the  interpretation  of  efficacy  and  safety  data,  leading  
to  a  need  for  national  and   international  collaboration   for  delivery  of  biologics  
registries   and   long-­term,   open   label   studies.   Development   of   new   biologics  
and   personalised   treatment   strategies   based   on   biology,   genetics   and  
pharmacogenetics   will   be   crucial   for   further   improvements   in   treatment  
options  and  patient  outcomes.  
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Table  1:  Description  of   the  end-­points  used   in  paediatric  rheumatology  
clinical  trials  [8,  9].  
  
PedACR   =   paediatric   American   College   of   Rheumatology   criteria,   ESR   =  
erythrocyte  sedimentation  rate,  CRP  =  c-­reactive  protein.  
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Figure  1:  Diagram  outlining  the  withdrawal  study  design  frequently  used  
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Table  2:  Adverse  events  related  to  different  anti-­TNF  agents  used  in  JIA  
–  data  mainly  from  long-­term  studies  and  biologics  registries    
  
  
ADA  =  adalimumab,  serious  adverse  events  =  SAEs.   ≈Safety  data  available  
from   the   original   clinical   trial   to   date.   ∞This   study   compared   patients   on  
methotrexate,   etanercept,   and   etanercept   plus  methotrexate,   and   found   the  
exposure-­adjusted  rates  of  SAEs  per  100  patient-­years  to  be  4.6,  7.1,  and  6.0  
respectively,  but   the  study  did  not  provide   the  absolute  number  of  SAEs.  ¥1  
case   of   malignancy   (thyroid   cancer).   ¶   3   cases   of   malignancy   (thyroid  
carcinoma,  yolk  sac  carcinoma,  non-­hodgkins  lymphoma).  *  3  non-­responder  
to   etanercept   subsequently   died   of   tuberculosis,   suspected   macrophage  
activation  syndrome  and  sepsis  whilst  on  other  immunosuppressives,  at  least  
8  months  post  etanercept  discontinuation.  ≅The  first  died  at  week  2  of  the  trial,  
10   days   after   a   placebo   infusion   from   septic   shock   and   an   associated  
deterioration  in  cardiac  function.  The  second  patient  had  SoJIA,  experienced  
a   severe   flare   of   their   disease   and   died   of   a   cardiac   arrest   3  months   after  
discontinuation   of   infliximab   (in   the   3mg/kg   infliximab   group),   whilst   in   the  
open  label  extension  phase  of  the  study.  
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Table  3:  Main  adverse  events  reported  in  association  with  anti-­TNF  use  
in  children  with  rheumatic  diseases  [17,  18,  27-­30,  44,  46,  70,  123-­127]  
  
  
AE  =  adverse  event,  TNF  =  tumor  necrosis  factor,  ADA  =  adalimumab,  MAS  =  
macrophage   activation   syndrome,   CPK   =   creatinine   phosphokinase,   CD   =  
crohns   disease,   UC   =   ulcerative   colitis,   ALT      =   alanine   aminotransferases,  
AST  =  aspartate  aminotransferases,  CMV  =  cytomegalovirus,  EBV  =  Epstein  
Barr   virus,   JSLE   =   juvenile   onset   systemic   lupus   erythematosus,   DM   =  
diabetes   mellitus.   §Reported   infusion   reactions   to   infliximab   include  
anaphylaxis,   vomiting,   fever,   headache,   hypotension,   abdominal   pain,  
coughing,   face  oedema,   rash,   urticaria,   chills,   fatigue,   sleepiness,   insomnia.  
*Described   by   the   FDA   US   Healthcare   AE   Reporting   System.   ¶Deaths  
described  in  table  2.    
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Table   4:   Adverse   events   reported   in   association   with   interleukin-­1  
receptor  blockers  
  
IL-­1   =   interleukin-­1,  macrophage   activation   syndrome  =  MAS,  CD  =   crohns  
disease,   CMV   =   cytomegalovirus,   upper   respiratory   tract   infection   =   URTI,    
*One  patient  had  urosepsis  and  MAS  whilst  on  placebo  (following  eight  doses  
of   canakinumab).   The   second   patient   died   of   MAS   and   severe   pulmonary  
hypertension   whilst   on   Canakinumab.  
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Table   5:   Adverse   events   reported   in   association   with   tocilizumab   and  
abatacept  use  [4,  104-­106,  108,  109]  
  
  
AE   =   adverse   event,   URTI   =   upper   respiratory   tract   infections.   ♯Developed  
after   19  months   of   abatacept   treatment.   §Diagnosed   at   day   89   of   the   open-­
label   lead   in  phase  and   thought   to  have  been   initially  misdiagnosed  as  JIA.  
≅dizziness,  nausea,  vomiting,  headache,  hypersensitivity,  rhinitis.  *Four  benign  
neoplasms  were  reported  but  no  malignancies.    
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PRINTO  =  Paediatric  Rheumatology   International  Trials  Organisation,  PRES  
=  Pediatric  Rheumatology  European  Society    
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